List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2192268/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tachykinin receptors and tachykinin receptor antagonists. Autonomic and Autacoid Pharmacology, 1993, 13, 23-93.	0.6	590
2	Antibodies from patients with rheumatoid arthritis target citrullinated histone 4 contained in neutrophils extracellular traps. Annals of the Rheumatic Diseases, 2014, 73, 1414-1422.	0.9	209
3	Synthesis and Conformational Analysis of a Cyclic Peptide Obtained via <i>i</i> to <i>i</i> +4 Intramolecular Side-Chain to Side-Chain Azideâ~Alkyne 1,3-Dipolar Cycloaddition. Journal of Organic Chemistry, 2008, 73, 5663-5674.	3.2	170
4	Competitive antagonists discriminate between NK <sub>2</sub> tachykinin receptor subtypes. British Journal of Pharmacology, 1990, 100, 588-592.	5.4	164
5	N-Triazinylammonium Tetrafluoroborates. A New Generation of Efficient Coupling Reagents Useful for Peptide Synthesis. Journal of the American Chemical Society, 2005, 127, 16912-16920.	13.7	142
6	The rat isolated portal vein: a preparation sensitive to neurokinins, particularly neurokinin B. European Journal of Pharmacology, 1987, 134, 321-326.	3.5	131
7	Di-(2-Ethylhexyl) Phthalate and Autism Spectrum Disorders. ASN Neuro, 2012, 4, AN20120015.	2.7	127
8	An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 10273-10278.	7.1	111
9	Structure-activity studies of neurokinin A. Neuropeptides, 1989, 13, 263-270.	2.2	105
10	In vivo evidence for tachykininergic transmission using a new NK-2 receptor-selective antagonist, MEN 10,376. Journal of Pharmacology and Experimental Therapeutics, 1991, 257, 1172-8.	2.5	103
11	The activity of peptides of the endothelin family in various mammalian smooth muscle preparations. European Journal of Pharmacology, 1989, 174, 23-31.	3.5	102
12	Cu <sup>I</sup> â€Catalyzed Azide–Alkyne Intramolecular <i>i</i> â€toâ€{ <i>i</i> +4) Sideâ€Chainâ€toâ€Sideá Cyclization Promotes the Formation of Helixâ€Like Secondary Structures. European Journal of Organic Chemistry, 2010, 2010, 446-457.	à€Chain 2.4	101
13	Tachykinin Receptors and Noncholinergic Bronchoconstriction in the Guinea-Pig Isolated Bronchi. The American Review of Respiratory Disease, 1991, 144, 363-367.	2.9	99
14	Synthesis of cyclic peptides on solid support. Tetrahedron Letters, 1991, 32, 2639-2642.	1.4	96
15	The actions of kinin antagonists on B1 and B2 receptor systems. European Journal of Pharmacology, 1986, 123, 61-65.	3.5	92
16	Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. British Journal of Pharmacology, 2003, 140, 1155-1158.	5.4	92
17	A potent and selective agonist for NK-2 tachykinin receptor. Peptides, 1989, 10, 593-595.	2.4	90
18	A New, Potent Urotensin II Receptor Peptide Agonist Containing a Pen Residue at the Disulfide Bridge. Journal of Medicinal Chemistry, 2002, 45, 4391-4394.	6.4	87

#	Article	IF	CITATIONS
19	The C-terminal hexapeptide, endothelin-(16–21), discriminates between different endothelin receptors. European Journal of Pharmacology, 1989, 166, 121-122.	3.5	84
20	Tachykinin receptors in the guinea-pig isolated bronchi. European Journal of Pharmacology, 1991, 197, 167-174.	3.5	77
21	Further evidence for the existence of NK <sub>2</sub> tachykinin receptor subtypes. British Journal of Pharmacology, 1991, 104, 91-96.	5.4	74
22	NK2 tachykinin receptors and contraction of circular muscle of the human colon: characterization of the NK2 receptor subtype. European Journal of Pharmacology, 1991, 203, 365-370.	3.5	69
23	On-resin head-to-tail cyclization of cyclotetrapeptides: optimization of crucial parameters. Journal of Peptide Science, 2004, 10, 218-228.	1.4	61
24	Putative odorant-binding protein in antennae and legs of carausius morosus (Insecta, Phasmatodea). Insect Biochemistry and Molecular Biology, 1996, 26, 19-24.	2.7	60
25	The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis. Journal of Neuroimmunology, 2005, 167, 131-137.	2.3	56
26	Conversion of kinins and their antagonists into B1 receptor activators and blockers in isolated vessels. European Journal of Pharmacology, 1986, 127, 219-224.	3.5	55
27	A Convenient Microwave-Enhanced Solid-Phase Synthesis of Difficult Peptide Sequences: Case Study of Gramicidin A and CSF114(Glc). International Journal of Peptide Research and Therapeutics, 2007, 13, 203-208.	1.9	54
28	Π virus levels in the plasma of infected individuals with different hepatic and extrahepatic pathology. Journal of Medical Virology, 2001, 63, 189-195.	5.0	53
29	A highly selective NK-2 tachykinin receptor antagonist containing D-tryptophan. European Journal of Pharmacology, 1990, 175, 113-115.	3.5	51
30	NK-2 Receptor Agonists and Antagonists. Annals of the New York Academy of Sciences, 1991, 632, 184-191.	3.8	51
31	Neurokinin receptors in the rat lower urinary tract. Journal of Pharmacology and Experimental Therapeutics, 1988, 246, 308-15.	2.5	49
32	Inhibition of Feline Immunodeficiency Virus Infectionin Vitroby Envelope Glycoprotein Synthetic Peptides. Virology, 1996, 220, 274-284.	2.4	46
33	Design, Synthesis, Conformational Analysis, and Biological Studies of Urotensin-II Lactam Analogues. Bioorganic and Medicinal Chemistry, 2002, 10, 3731-3739.	3.0	45
34	Biological activity of N-terminal fragments of calcitonin gene-related peptide. European Journal of Pharmacology, 1990, 179, 217-219.	3.5	43
35	Motor response of the human isolated small intestine and urinary bladder to porcine neuromedin Uâ€8. British Journal of Pharmacology, 1990, 99, 186-188.	5.4	43
36	Unraveling the Active Conformation of Urotensin II. Journal of Medicinal Chemistry, 2004, 47, 1652-1661.	6.4	43

#	Article	IF	CITATIONS
37	Effect of synthetic tachykinin analogues on airway microvascular leakage in rats and guineaâ€pigs: evidence for the involvement of NKâ€1 receptors. Autonomic and Autacoid Pharmacology, 1991, 11, 267-276.	0.6	42
38	Autoantibodies directed against ribosomal P proteins: use of a multiple antigen peptide as the coating agent in ELISA. Journal of Immunological Methods, 1995, 179, 193-202.	1.4	42
39	Activity of peptide and non-peptide antagonists at peripheral NK1 receptors. European Journal of Pharmacology, 1992, 215, 93-98.	3.5	40
40	CGRP antagonist activity of short fragments of human αCGRP, CGRP(23–37) and CGRP(19–37). Peptides, 1992, 13, 1025-1027.	2.4	39
41	A GαsCarboxyl-Terminal Peptide Prevents GsActivation by the A2AAdenosine Receptor. Molecular Pharmacology, 2000, 58, 226-236.	2.3	39
42	Antiviral Activity and Conformational Features of an Octapeptide Derived from the Membrane-Proximal Ectodomain of the Feline Immunodeficiency Virus Transmembrane Glycoprotein. Journal of Virology, 2003, 77, 3724-3733.	3.4	39
43	Racemization studies of Fmoc-Ser(tBu)-OH during stepwise continuous-flow solid-phase peptide synthesis. Tetrahedron Letters, 1998, 39, 8529-8532.	1.4	38
44	Side chainâ€ŧoâ€side chain cyclization by click reaction. Journal of Peptide Science, 2009, 15, 451-454.	1.4	38
45	NK-1 receptors mediate the tachykinin stimulation of salivary secretion: selective agonists provide further evidence. European Journal of Pharmacology, 1988, 150, 377-379.	3.5	37
46	Contractile response of the human isolated urinary bladder to neurokinins: involvement of NK-2 receptors. European Journal of Pharmacology, 1988, 145, 335-340.	3.5	37
47	The hamster isolated trachea: a new preparation for studying NK-2 receptors. European Journal of Pharmacology, 1989, 166, 435-440.	3.5	37
48	In vivo pharmacology of [βAla8]neurokinin A-(4-10), a selective NK-2 tachykinin receptor agonist. European Journal of Pharmacology, 1990, 177, 81-86.	3.5	37
49	Electrochemical Investigation of Melittin Reconstituted into a Mercury-Supported Lipid Bilayer. Langmuir, 2006, 22, 6644-6650.	3.5	37
50	1,4-Disubstituted-[1,2,3]triazolyl-Containing Analogues of MT-II: Design, Synthesis, Conformational Analysis, and Biological Activity. Journal of Medicinal Chemistry, 2014, 57, 9424-9434.	6.4	37
51	Conformational Analysis of a Glycosylated Human Myelin Oligodendrocyte Glycoprotein Peptide Epitope Able To Detect Antibody Response in Multiple Sclerosis. Journal of Medicinal Chemistry, 2001, 44, 2378-2381.	6.4	36
52	Conformationâ^'Activity Relationship of Designed Glycopeptides as Synthetic Probes for the Detection of Autoantibodies, Biomarkers of Multiple Sclerosis. Journal of Medicinal Chemistry, 2006, 49, 5072-5079.	6.4	36
53	Effects of tachykinins and selective tachykinin receptor agonists on vascular permeability in the rat lower urinary tract: evidence for the involvement of NKâ€1 receptors. Autonomic and Autacoid Pharmacology, 1989, 9, 253-264.	0.6	35
54	The peptide binding specificity of HLA-B27 subtypes. Immunogenetics, 1994, 40, 192-198.	2.4	34

#	Article	IF	CITATIONS
55	Analysis of transglutaminase protein substrates by functional proteomics. Protein Science, 2003, 12, 1290-1297.	7.6	34
56	Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Frontiers in Chemistry, 2020, 8, 572923.	3.6	33
57	Further studies on the motor response of the human isolated urinary bladder to tachykinins, capsaicin and electrical field stimulation. General Pharmacology, 1989, 20, 663-669.	0.7	30
58	Structure-Activity Study of Neurokinins: Antagonists for the Neurokinin-2 Receptor. Pharmacology, 1990, 41, 184-194.	2.2	30
59	<i>N</i> <sup>α</sup> â€Fmocâ€Protected ï‰â€Azido―and ï‰â€Alkynylâ€ <scp>L</scp> â€amino Acids as Bi the Synthesis of "Clickable―Peptides. European Journal of Organic Chemistry, 2008, 2008, 5308-5314.	uilding Blo 2.4	ocksfor
60	Effect of thiorphan on response of the guinea-pig gallbladder to tachykinins. European Journal of Pharmacology, 1989, 165, 51-61.	3.5	29
61	The importance of secondary anchor residue motifs of HLA class I proteins: A chemometric approach. Molecular Immunology, 1994, 31, 549-554.	2.2	29
62	Synthesis, structural aspects and bioactivity of the marine cyclopeptide hymenamide C. Tetrahedron, 2001, 57, 6249-6255.	1.9	29
63	Conformation-activity relationship of tachykinin neurokinin A(4-10) and of some [Xaa8] analogs. Biochemistry, 1991, 30, 10175-10181.	2.5	28
64	The membrane-proximal tryptophan-rich region in the transmembrane glycoprotein ectodomain of feline immunodeficiency virus is important for cell entry. Virology, 2004, 320, 156-166.	2.4	28
65	Designed Glycopeptides with Different Î <sup>2</sup> -Turn Types as Synthetic Probes for the Detection of Autoantibodies as Biomarkers of Multiple Sclerosis. Journal of Medicinal Chemistry, 2008, 51, 5304-5309.	6.4	28
66	Effect of thiorphan on tachykinin-induced potentiation of nerve-mediated contractions of the rat isolated vas deferens. Journal of Pharmacology and Experimental Therapeutics, 1989, 250, 678-81.	2.5	28
67	A New Class of Pseudopeptide Antagonists of the Kinin B1 Receptor Containing Alkyl Spacers. Journal of Medicinal Chemistry, 1999, 42, 409-414.	6.4	27
68	SPPS of difficult sequences. Chemical Biology and Drug Design, 1997, 49, 103-111.	1.1	27
69	Glycopeptide-Based Antibody Detection in Multiple Sclerosis by Surface Plasmon Resonance. Sensors, 2012, 12, 5596-5607.	3.8	27
70	Synthesis of the bradykinin B1 antagonist [desArg10]HOE 140 on 2-chlorotrityl resin. International Journal of Peptide Research and Therapeutics, 1996, 2, 319-323.	0.1	26
71	Title is missing!. International Journal of Peptide Research and Therapeutics, 2002, 9, 119-123.	0.1	26
72	Urotensin-II Receptor Antagonists. Current Medicinal Chemistry, 2006, 13, 267-275.	2.4	26

#	Article	IF	CITATIONS
73	Rett syndrome: An autoimmune disease?. Autoimmunity Reviews, 2016, 15, 411-416.	5.8	25
74	Tachykinins protect against ethanol-induced gastric lesions in rats. Peptides, 1989, 10, 79-81.	2.4	24
75	Effect of endothelin-1, endothelin-3 and C-terminal hexapeptide, endothelin (16–21) on motor activity in rats. Neuropeptides, 1990, 16, 21-24.	2.2	24
76	Structureâ€activity studies on endothelin (16–21), the Câ€ŧerminal hexapeptide of the endothelins, in the guineaâ€pig bronchus. British Journal of Pharmacology, 1990, 101, 232-234.	5.4	24
77	Urotensin-II Receptor Ligands. From Agonist to Antagonist Activity. Journal of Medicinal Chemistry, 2005, 48, 7290-7297.	6.4	24
78	Exploring interaction of β-amyloid segment (25–35) with membrane models through paramagnetic probes. Journal of Peptide Science, 2006, 12, 766-774.	1.4	24
79	Posttranslationally modified peptides efficiently mimicking neoantigens: A challenge for theragnostics of autoimmune diseases. Biopolymers, 2010, 94, 791-799.	2.4	24
80	Characterization of the tachykinin neurokinin-2 receptor in the human urinary bladder by means of selective receptor antagonists and peptidase inhibitors. Journal of Pharmacology and Experimental Therapeutics, 1993, 267, 590-5.	2.5	24
81	Synthetic Peptides in the Diagnosis of HIV Infection. Current Protein and Peptide Science, 2003, 4, 285-290.	1.4	23
82	Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology, 2005, 65, 781-782.	1.1	23
83	Conventional and microwaveâ€assisted SPPS approach: a comparative synthesis of PTHrP(1–34)NH <sub>2</sub> . Journal of Peptide Science, 2011, 17, 708-714.	1.4	23
84	Antibodies from multiple sclerosis patients preferentially recognize hyperglucosylated adhesin of non-typeable Haemophilus influenzae. Scientific Reports, 2016, 6, 39430.	3.3	23
85	Anchor residue motifs of HLA class-I-binding peptides analyzed by the direct binding of synthetic peptides to HLA class I $\hat{I}\pm$ chains. Human Immunology, 1993, 38, 187-192.	2.4	22
86	New Insight into the Binding Mode of Peptide Ligands at Urotensin-II Receptor: Structureâ^'Activity Relationships Study on P5U and Urantide. Journal of Medicinal Chemistry, 2009, 52, 3927-3940.	6.4	22
87	Designed Glucopeptides Mimetics of Myelin Protein Epitopes As Synthetic Probes for the Detection of Autoantibodies, Biomarkers of Multiple Sclerosis. Journal of Medicinal Chemistry, 2012, 55, 10437-10447.	6.4	22
88	HLA class I binding of synthetic nonamer peptides carrying major anchor residue motifs of HLA-B27 (B*2705)-binding peptides. Immunogenetics, 1993, 38, 41-46.	2.4	20
89	Biosensor analysis of anti-citrullinated protein/peptide antibody affinity. Analytical Biochemistry, 2014, 465, 96-101.	2.4	20
90	Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations. Clinical Rheumatology, 2018, 37, 1407-1411.	2.2	20

#	Article	IF	CITATIONS
91	Interaction of amyloid β protein (25–35) with tachykinin receptors. Neuropeptides, 1992, 22, 99-101.	2.2	19
92	Development of Antiviral Fusion Inhibitors: Short Modified Peptides Derived from the Transmembrane Glycoprotein of Feline Immunodeficiency Virus. ChemBioChem, 2006, 7, 774-779.	2.6	19
93	A Membrane-Permeable Peptide Containing the Last 21 Residues of the Cî±S Carboxyl Terminus Inhibits CS-Coupled Receptor Signaling in Intact Cells: Correlations between Peptide Structure and Biological Activity. Molecular Pharmacology, 2006, 69, 727-736.	2.3	19
94	Neurokinins induce a relaxation of the rat duodenum "in vivo" by activating postganglionic sympathetic elements in prevertebral ganglia: involvement of an NK-2 type of neurokinin receptor. Journal of Pharmacology and Experimental Therapeutics, 1988, 246, 322-7.	2.5	19
95	The Contractile Effect of Tachykinins on Human Prostatic Urethra: Involvement of NK-2 Receptors. Journal of Urology, 1990, 144, 1543-1545.	0.4	18
96	Affinity of R 396, an NK-2 tachykinin receptor antagonist, for NK-2 receptors in preparations from different species. Neuropeptides, 1992, 22, 93-98.	2.2	18
97	Probing the Topological Arrangement of the N- and C-Terminal Residues of Bradykinin for Agonist Activity at the B1 Receptor. Journal of Medicinal Chemistry, 1999, 42, 3369-3377.	6.4	18
98	Structural Studies on Hgr3 Orphan Receptor Ligand Prolactin-Releasing Peptide. Journal of Medicinal Chemistry, 2002, 45, 5483-5491.	6.4	18
99	Recent Structure-Activity Studies of the Peptide Hormone Urotensin-II, a Potent Vasoconstrictor. Current Medicinal Chemistry, 2004, 11, 969-979.	2.4	18
100	Solidâ€phase synthesis of neurokinin A antagonists. International Journal of Peptide and Protein Research, 1991, 37, 140-144.	0.1	18
101	Immune Dysfunction in Rett Syndrome Patients Revealed by High Levels of Serum Anti-N(Glc) IgM Antibody Fraction. Journal of Immunology Research, 2014, 2014, 1-6.	2.2	18
102	Surface plasmon resonance-based methodology for anti-adalimumab antibody identification and kinetic characterization. Analytical and Bioanalytical Chemistry, 2015, 407, 7477-7485.	3.7	18
103	Trimeric SARS-CoV-2 Spike Proteins Produced from CHO Cells in Bioreactors Are High-Quality Antigens. Processes, 2020, 8, 1539.	2.8	18
104	Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry. Chemistry and Biodiversity, 2021, 18, e2000833.	2.1	18
105	Urotensin-II receptor peptide agonists. Medicinal Research Reviews, 2004, 24, 577-588.	10.5	17
106	Surface plasmon resonance, fluorescence, and circular dichroism studies for the characterization of the binding of BACE-1 inhibitors. Analytical and Bioanalytical Chemistry, 2013, 405, 827-835.	3.7	17
107	Analogs of neurokinin A(4–10) afford protection against gastroduodenal ulcers in rats. Peptides, 1990, 11, 293-297.	2.4	16
108	Detection and epitope mapping of immunoreactive human endothelin-1 using ELISA and a surface plasmon resonance-based biosensor. Biosensors and Bioelectronics, 1997, 12, 765-778.	10.1	16

#	Article	IF	CITATIONS
109	Label-free method for anti-glucopeptide antibody detection in Multiple Sclerosis. MethodsX, 2015, 2, 141-144.	1.6	16
110	Triazole-Modified Peptidomimetics: An Opportunity for Drug Discovery and Development. Frontiers in Chemistry, 2021, 9, 674705.	3.6	16
111	Tachykinin receptor antagonists and potential clinical applications at peripheral level. Biochemical Society Transactions, 1991, 19, 909-912.	3.4	15
112	Heterogeneity of tachykinin NK-2 receptors in rabbit, guinea-pig and human smooth muscles. Neuropeptides, 1992, 23, 181-186.	2.2	15
113	An Immunodominant Epitope in a Functional Domain Near the N-Terminus of Human Granulocyte-Macrophage Colony-Stimulating Factor Identified by Cross-Reaction of Synthetic Peptides with Neutralizing Anti-Protein and Anti-Peptide Antibodies. Hybridoma, 1994, 13, 457-468.	0.6	15
114	Structures and Micelle Locations of the Nonlipidated and Lipidated C-Terminal Membrane Anchor of 2â€~,3â€~-Cyclic Nucleotide-3â€~-phosphodiesterase. Biochemistry, 2008, 47, 308-319.	2.5	15
115	Building blocks for the synthesis of postâ€translationally modified glycated peptides and proteins. Journal of Peptide Science, 2009, 15, 67-71.	1.4	15
116	Antibody Recognition in multiple sclerosis and rett syndrome using a collection of linear and cyclic <i>N</i> â€glucosylated antigenic probes. Biopolymers, 2015, 104, 560-576.	2.4	15
117	Synthesis of a Dicarba-Analog of Octreotide Keeping the Type II β -Turn of the Pharmacophore in Water Solution. Letters in Organic Chemistry, 2005, 2, 274-279.	0.5	15
118	Synthesis and Rearrangement of Cycloadducts from Trimethylsilanecarbonitrile Oxide. Heterocycles, 1983, 20, 511.	0.7	15
119	Role of D-tryptophan for affinity of MEN 10207 tachykinin antagonist at NK2 receptors. Peptides, 1991, 12, 1015-1018.	2.4	14
120	Rapid Simultaneous Determination of Tryptophan and Tyrosine in Synthetic Peptides by Derivative Spectroscopy. Journal of Pharmaceutical Sciences, 1993, 82, 179-182.	3.3	14
121	Alpha Actinin is Specifically Recognized by Multiple Sclerosis Autoantibodies Isolated Using an N-Clucosylated Peptide Epitope. Molecular and Cellular Proteomics, 2013, 12, 277-282.	3.8	14
122	First studies on tumor associated carbonic anhydrases IX and XII monoclonal antibodies conjugated to small molecule inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 592-596.	5.2	14
123	Role of C-terminal amidation on the biological activity of neurokinin A derivatives with agonist and antagonist properties. Journal of Pharmacology and Experimental Therapeutics, 1993, 264, 17-21.	2.5	14
124	Feline Immunodeficiency Virus Plasma Load Reduction by a Retroinverso Octapeptide Reproducing the Trp-Rich Motif of the Transmembrane Glycoprotein. Antiviral Therapy, 2005, 10, 671-680.	1.0	14
125	Differences in peptide-binding specificity of two ankylosing spondylitis-associated HLA-B27 subtypes. Immunogenetics, 1995, 42, 123-8.	2.4	13
126	Synthesis and biological activity of new bradykinin pseudopeptide B1 receptor agonists containing alkylic spacers. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 2661-2664.	2.2	13

#	Article	IF	CITATIONS
127	Physicochemical characterization of a peptide deriving from the glycoprotein gp36 of the feline immunodeficiency virus and its lipoylated analogue in micellar systems. Biochimica Et Biophysica Acta - Biomembranes, 2006, 1758, 1653-1661.	2.6	13
128	Fmoc-protected iminosugar modified asparagine derivatives as building blocks for glycomimetics-containing peptides. Bioorganic and Medicinal Chemistry, 2007, 15, 3965-3973.	3.0	13
129	Synthesis and biological activity of N-methylated analogues of Neukokinin A. Neuropeptides, 1987, 10, 355-359.	2.2	12
130	Retroinverso Analogue of the Antiviral Octapeptide C8 Inhibits Feline Immunodeficiency Virus in Serum. Journal of Medicinal Chemistry, 2003, 46, 1807-1810.	6.4	12
131	Antibodies Generated in Cats by a Lipopeptide Reproducing the Membrane-Proximal External Region of the Feline Immunodeficiency Virus Transmembrane Enhance Virus Infectivity. Vaccine Journal, 2007, 14, 944-951.	3.1	12
132	Synthesis of new ribosylated Asn building blocks as useful tools for glycopeptide and glycoprotein synthesis. Tetrahedron Letters, 2009, 50, 4151-4153.	1.4	12
133	Divergent and convergent synthesis of polymannosylated dibranched antigenic peptide of the immunodominant epitope MBP(83–99). Bioorganic and Medicinal Chemistry, 2013, 21, 6718-6725.	3.0	12
134	Copper-Catalyzed Azide-Alkyne Cycloaddition (CuAAC)-Mediated Macrocyclization of Peptides: Impact on Conformation and Biological Activity. Current Topics in Medicinal Chemistry, 2018, 18, 591-610.	2.1	12
135	TT virus levels in the plasma of infected individuals with different hepatic and extrahepatic pathology. Journal of Medical Virology, 2001, 63, 189-95.	5.0	12
136	Synthesis and biological activity of NK-2 selective tachykinin antagonists containing D-tryptophan. Peptides, 1990, 11, 619-620.	2.4	11
137	Peptide-based tachykinin NK2 receptor antagonists. Medicinal Research Reviews, 1995, 15, 139-155.	10.5	11
138	Conformational studies on a synthetic C-terminal fragment of the α subunit of GS proteins. Biopolymers, 2000, 54, 186-194.	2.4	11
139	Dissection of seroreactivity against the tryptophan-rich motif of the feline immunodeficiency virus transmembrane glycoprotein. Virology, 2004, 322, 360-369.	2.4	11
140	Fingerprinting of anti-citrullinated protein antibodies (ACPA): specificity, isotypes and subclasses. Lupus, 2015, 24, 433-441.	1.6	11
141	Mechanisms of HIV-1 Nucleocapsid Protein Inhibition by Lysyl-Peptidyl-Anthraquinone Conjugates. Bioconjugate Chemistry, 2016, 27, 247-256.	3.6	11
142	Mapping of Monoclonal Antibody- and Receptor-Binding Domains on Human Granulocyte—Macrophage Colony-Stimulating Factor (rhGM-CSF) Using a Surface Plasmon Resonance-Based Biosensor. Hybridoma, 1996, 15, 343-350.	0.6	10
143	Toward biomarkers in multiple sclerosis: new advances. Expert Review of Neurotherapeutics, 2006, 6, 781-794.	2.8	10
144	Synthesis of diastereomerically pure Lys( <i>N</i> <sup>ε</sup> â€lipoyl) building blocks and their use in Fmoc/tBu solid phase synthesis of lipoylâ€containing peptides for diagnosis of primary biliary cirrhosis. Journal of Peptide Science, 2015, 21, 408-414.	1.4	10

#	Article	IF	CITATIONS
145	An Optimised Di-Boronate-ChemMatrix Affinity Chromatography to Trap Deoxyfructosylated Peptides as Biomarkers of Glycation. Molecules, 2020, 25, 755.	3.8	10
146	Characterization of NF-ήB Reporter U937 Cells and Their Application for the Detection of Inflammatory Immune-Complexes. PLoS ONE, 2016, 11, e0156328.	2.5	10
147	Chemometric approach to a QSAR study of peptides behaving as NK-2 receptor antagonists. Tetrahedron Computer Methodology, 1990, 3, 379-387.	0.2	9
148	NKâ€l Receptors and VascularPermeability in Rat Airways. Annals of the New York Academy of Sciences, 1991, 632, 358-359.	3.8	9
149	Structure-activity study of the C-terminal residue of MEN 10207 tachykinin antagonist. Peptides, 1992, 13, 207-208.	2.4	9
150	GR 73,632 and [Glu(OBzl)11]substance P are selective agonists for the septide-sensitive tachykinin NK1 receptor in the rat urinary bladder. Neuropeptides, 1995, 28, 99-106.	2.2	9
151	Investigation of Newly Synthesized Peptides by Capillary Zone Electrophoresis/Electrospray Mass Spectrometry. , 1996, 10, 1128-1132.		9
152	Driving Forces in the Delivery of Penetratin Conjugated G Protein Fragment. Journal of Medicinal Chemistry, 2007, 50, 1458-1464.	6.4	9
153	Intracerebroventricular administration of endothelins: effects on the suprasptnal micturition reflex and blood pressure in the anaesthetized rat. European Journal of Pharmacology, 1991, 199, 201-207.	3.5	8
154	Solid-phase synthesis and dimerization of an azobenzene-containing peptide as photoisomerizable proteinase inhibitor. International Journal of Peptide Research and Therapeutics, 1995, 2, 27-32.	0.1	8
155	Agonist Activity at the Kinin B1 Receptor:Â Structural Requirements of the Central Tetrapeptide. Journal of Medicinal Chemistry, 2001, 44, 274-278.	6.4	8
156	Conformational analysis of the G?s proteinC-terminal region. Journal of Peptide Science, 2002, 8, 476-488.	1.4	8
157	A structure–activity relationship study on position-2 of the Gαs C-terminal peptide able to inhibit Gs activation by A2A adenosine receptor. European Journal of Medicinal Chemistry, 2003, 38, 13-18.	5.5	8
158	IgG and IgM antibodies to the refolded MOG1–125 extracellular domain in humans. Journal of Neuroimmunology, 2011, 233, 216-220.	2.3	8
159	Epitope mapping of antiâ€myelin oligodendrocyte glycoprotein (MOG) antibodies in a mouse model of multiple sclerosis: microwaveâ€assisted synthesis of the peptide antigens and ELISA screening. Journal of Peptide Science, 2016, 22, 52-58.	1.4	8
160	Fine Mapping of Glutamate Decarboxylase 65 Epitopes Reveals Dependency on Hydrophobic Amino Acids for Specific Interactions. International Journal of Molecular Sciences, 2019, 20, 2909.	4.1	8
161	Structure-Activity Analysis of C-Terminal Endothelin Analogues. Journal of Cardiovascular Pharmacology, 1998, 31, S251-S254.	1.9	8
162	Feline immunodeficiency virus plasma load reduction by a retroinverso octapeptide reproducing the Trp-rich motif of the transmembrane glycoprotein. Antiviral Therapy, 2005, 10, 671-80.	1.0	8

#	Article	IF	CITATIONS
163	Augmentation of the affinity of HLA class I-binding peptides lacking primary anchor residues by manipulation of the secondary anchor residues. Journal of Peptide Science, 1995, 1, 266-273.	1.4	7
164	Role of Lipoylation of the Immunodominant Epitope of Pyruvate Dehydrogenase Complex: Toward a Peptide-Based Diagnostic Assay for Primary Biliary Cirrhosis. Journal of Medicinal Chemistry, 2015, 58, 6619-6629.	6.4	7
165	Serpin A1 and the modulation of type I collagen turnover: Effect of the Câ€terminal peptide 409–418 (SA1â€III) in human dermal fibroblasts. Cell Biology International, 2018, 42, 1340-1348.	3.0	7
166	Design, synthesis, and conformational studies of [DOTA]â€Octreotide analogs containing [1,2,3]triazolyl as a disulfide mimetic. Peptide Science, 2018, 110, e24071.	1.8	7
167	Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques. Analytical Biochemistry, 2019, 566, 133-138.	2.4	7
168	Onâ€resin microwaveâ€assisted copperâ€catalyzed azideâ€alkyne cycloaddition of H1â€relaxin B single chain â€~stapled' analogues. Peptide Science, 2020, 112, e24159.	1.8	7
169	An Optimized Scalable Fully Automated Solid-Phase Microwave-Assisted cGMP-Ready Process for the Preparation of Eptifibatide. Organic Process Research and Development, 2021, 25, 552-563.	2.7	7
170	Structure-activity relationship study of R396, an NK2 tachykinin antagonist selective for the NK2B receptor subtype. Neuropeptides, 1992, 23, 143-145.	2.2	6
171	Side reactions in peptide synthesis: Dehydration of C-terminal aspartylamide peptides during side chain to side chain to side chain cyclization. Tetrahedron Letters, 1993, 34, 2199-2200.	1.4	6
172	Investigation of Newly Synthesized Endothelin Peptides by High-performance Liquid Chromatography Coupled to Electrospray Mass Spectrometry. Rapid Communications in Mass Spectrometry, 1996, 10, 1504-1508.	1.5	6
173	Toward the rational development of peptidomimetic analogs of the C-terminal endothelin hexapeptide: development of a theoretical model. Il Farmaco, 1998, 53, 545-556.	0.9	6
174	The Antiviral Activity of a Synthetic Peptide Derived from the Envelope SU Glycoprotein of Feline Immunodeficiency Virus Maps in Correspondence of an Amphipathic Helical Segment. Biochemical and Biophysical Research Communications, 1998, 246, 160-165.	2.1	6
175	Synthetic Peptides Reproducing Tissue Transglutaminase–Cliadin Complex Neo-epitopes as Probes for Antibody Detection in Celiac Disease Patients' Sera. Journal of Medicinal Chemistry, 2015, 58, 1390-1399.	6.4	6
176	Serpinâ€A1 Câ€Terminal Peptides as Collagen Turnover Modulators. ChemMedChem, 2016, 11, 1850-1855.	3.2	6
177	Label-free detection of immune complexes with myeloid cells. Clinical and Experimental Immunology, 2016, 185, 72-80.	2.6	6
178	Multiplex determination of antigen specific antibodies with cell binding capability in a self-driven microfluidic system. Sensors and Actuators B: Chemical, 2017, 238, 1092-1097.	7.8	6
179	Antibodies to post-translationally modified mitochondrial peptide PDC-E2(167–184) in type 1 diabetes. Archives of Biochemistry and Biophysics, 2018, 659, 66-74.	3.0	6
180	Peptides and Peptidomimetics as Inhibitors of Enzymes Involved in Fibrillar Collagen Degradation. Materials, 2021, 14, 3217.	2.9	6

#	Article	IF	CITATIONS
181	Surface Plasmon Resonance Method to Evaluate Anti-citrullinated Protein/Peptide Antibody Affinity to Citrullinated Peptides. Methods in Molecular Biology, 2015, 1348, 267-274.	0.9	6
182	Neurokinin A-(4–10): a potent bronchospastic agent virtually devoid of sialologic properties in anaesthetized guinea-pigs. European Journal of Pharmacology, 1988, 148, 475-478.	3.5	5
183	Conformationally constrained tachykinins: N-methylated analogues of neurokinin A. Biopolymers, 1989, 28, 65-67.	2.4	5
184	Effect of intrathecal administration of ET-1, ET-3 and ET(16–21) on blood pressure and micturition reflex in anesthetized rats. Neurochemistry International, 1991, 18, 565-569.	3.8	5
185	Conformation of four peptides corresponding to the α-helical segments of human GM–CSF. , 1997, 3, 336-346.		5
186	Synthesis and biological properties of the seven alanine-modified analogues of the marine cyclopeptide hymenamide C. Journal of Peptide Science, 2002, 8, 407-417.	1.4	5
187	Title is missing!. International Journal of Peptide Research and Therapeutics, 2002, 9, 125-129.	0.1	5
188	Gαs proteinC-terminal α-helix at the interface: does the plasma membrane play a critical role in the Gαs protein functionality?. Journal of Peptide Science, 2005, 11, 617-626.	1.4	5
189	Evaluation of new immunological targets in neuromyelitis optica. Journal of Peptide Science, 2013, 19, 25-32.	1.4	5
190	Interaction Study of Phospholipid Membranes with an N-Glucosylated β-Turn Peptide Structure Detecting Autoantibodies Biomarkers of Multiple Sclerosis. Membranes, 2015, 5, 576-596.	3.0	5
191	Production of peptides as generic drugs: a patent landscape of octreotide. Expert Opinion on Therapeutic Patents, 2016, 26, 485-495.	5.0	5
192	Structure–Activity Relationship Studies, SPR Affinity Characterization, and Conformational Analysis of Peptides That Mimic the HNK″ Carbohydrate Epitope. ChemMedChem, 2017, 12, 751-759.	3.2	5
193	Glycoreplica peptides to investigate molecular mechanisms of immune-mediated physiological versus pathological conditions. Archives of Biochemistry and Biophysics, 2019, 663, 44-53.	3.0	5
194	A Multiple N-Glucosylated Peptide Epitope Efficiently Detecting Antibodies in Multiple Sclerosis. Brain Sciences, 2020, 10, 453.	2.3	5
195	Serological and Genetic Evidence for Altered Complement System Functionality in Systemic Lupus Erythematosus: Findings of the GAPAID Consortium. PLoS ONE, 2016, 11, e0150685.	2.5	5
196	Reactivity of Rheumatoid Arthritis-Associated Citrulline-Dependent Antibodies to Epstein-Barr Virus Nuclear Antigen1-3. Antibodies, 2022, 11, 20.	2.5	5
197	Seroreactivity of the Severe Acute Respiratory Syndrome Coronavirus 2 Recombinant S Protein, Receptor-Binding Domain, and Its Receptor-Binding Motif in COVID-19 Patients and Their Cross-Reactivity With Pre-COVID-19 Samples From Malaria-Endemic Areas. Frontiers in Immunology, 2022, 13, 856033.	4.8	5
198	N-terminal truncated analogs of men 10376 as tachykinin NK-2 receptor antagonists. Life Sciences, 1992, 51, 1929-1936.	4.3	4

PAOLO ROVERO

#	Article	IF	CITATIONS
199	[125I]His-neurokinin A binds selectively to NK2 receptors of the B-type in rat small intestine smooth muscle membranes. European Journal of Pharmacology, 1992, 227, 163-171.	2.6	4
200	Calcium-mediated endothelin signaling in C6 rat glioma cells. Neuropeptides, 1999, 33, 13-17.	2.2	4
201	Efficacy of an Amphipathic Oligopeptide to Shuttle and Release a <i>cis</i> -Acting DNA Decoy into Human Cells. BioTechniques, 2002, 32, 172-177.	1.8	4
202	Side chain-to-Side chain Cyclization by Intramolecular Click Reaction - Building Blocks, Solid Phase Synthesis and Conformational Characterization. Advances in Experimental Medicine and Biology, 2009, 611, 175-176.	1.6	4
203	<i>In vitro</i> inhibition of feline leukaemia virus infection by synthetic peptides derived from the transmembrane domain. Antiviral Therapy, 2011, 16, 905-913.	1.0	4
204	Human recombinant domain antibodies against multiple sclerosis antigenic peptide CSF114(Glc). Journal of Molecular Recognition, 2014, 27, 618-626.	2.1	4
205	Epitope mapping of the N-terminal portion of tissue transglutaminase protein antigen to identify linear epitopes in celiac disease. Journal of Peptide Science, 2014, 20, 689-695.	1.4	4
206	A novel DNA/histone H4 peptide complex detects autoantibodies in systemic lupus erythematosus sera. Arthritis Research and Therapy, 2016, 18, 220.	3.5	4
207	Synthesis of dicarba-cyclooctapeptide Somatostatin analogs by conventional and MW-assisted RCM: A study about the impact of the configuration at C $\hat{I}$ ± of selected amino acids. Chemical Engineering and Processing: Process Intensification, 2017, 122, 365-372.	3.6	4
208	Modeling interaction between gp120 HIV protein and CCR5 receptor. Journal of Peptide Science, 2019, 25, e3142.	1.4	4
209	Triterpene glycosides from Blighia welwitschii and evaluation of their antibody recognition capacity in multiple sclerosis. Phytochemistry, 2020, 176, 112392.	2.9	4
210	Susceptibility of cosmeceutical peptides to proteases activity: Development of dermal stability test by LC-MS/MS analysis. Journal of Pharmaceutical and Biomedical Analysis, 2021, 194, 113775.	2.8	4
211	Specificity of Anti-Citrullinated Protein Antibodies to Citrullinated α-Enolase Peptides as a Function of Epitope Structure and Composition. Antibodies, 2021, 10, 27.	2.5	4
212	Structure-Activity Relationships of Agonist and Antagonist Ligands. , 1994, , 329-365.		4
213	Selective capture of antiâ€Nâ€glucosylated NTHi adhesin peptide antibodies by a multivalent dextran conjugate. ChemBioChem, 2021, , .	2.6	4
214	Synthesis and biological activity of NK1 tachykinin antagonists not containing D-residues. Neuropeptides, 1994, 26, 55-57.	2.2	3
215	Binding of Human GM-CSF to Synthetic Peptides of the Alpha Subunit of Its Receptor. Journal of Receptor and Signal Transduction Research, 1996, 16, 77-92.	2.5	3
216	Design, synthesis and conformational analysis of hGM-CSF[13-31]-Gly-Pro-Gly-[103-116]. , 1997, 3, 323-335.		3

#	Article	IF	CITATIONS
217	Solution conformation of câ€[Glnâ€Trpâ€Pheâ€Glyâ€Leuâ€Met], a NKâ€2 tachykinin antagonist. International Jou of Peptide and Protein Research, 1994, 44, 556-561.	ırnal 0.1	3
218	Solvent independent conformational propensities of [1,2,3]triazolylâ€bridged parathyroid hormoneâ€related peptideâ€derived cycloâ€nonapeptide analogues. Biopolymers, 2012, 98, 535-545.	2.4	3
219	Humoral Response Against LLâ€37 in Psoriatic Disease: Comment on the Article by Yuan et al. Arthritis and Rheumatology, 2019, 71, 1964-1965.	5.6	3
220	Studies of membranotropic and fusogenic activity of two putative HCV fusion peptides. Biochimica Et Biophysica Acta - Biomembranes, 2019, 1861, 50-61.	2.6	3
221	Hyperglucosylated adhesinâ€derived peptides as antigenic probes in multiple sclerosis: Structure optimization and immunological evaluation. Journal of Peptide Science, 2020, 26, e3281.	1.4	3
222	Cross-reactive peptide epitopes of Enterovirus Coxsackie B4 and human glutamic acid decarboxylase detecting antibodies in latent autoimmune diabetes in adults versus type 1 diabetes. Clinica Chimica Acta, 2021, 515, 73-79.	1.1	3
223	A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis. Scientific Reports, 2021, 11, 16393.	3.3	3
224	Peptide Antibody Reactivity to Homologous Regions in Glutamate Decarboxylase Isoforms and Coxsackievirus B4 P2C. International Journal of Molecular Sciences, 2022, 23, 4424.	4.1	3
225	Effect of intravenous tachykinins and tachykinin -related peptides on vascular permeability in the rat lower urinary tract. Regulatory Peptides, 1988, 22, 27.	1.9	2
226	Solid support-dependent alkylation of tryptophan residues in SPPS using a 2-methoxybenzyl alcohol-based linker. International Journal of Peptide Research and Therapeutics, 1994, 1, 149-155.	0.1	2
227	Synthesis and biological activity of NK1 substance P selective agonists by modifying the methionyl residue. Neuropeptides, 1994, 27, 27-29.	2.2	2
228	Facile reduction of peptide oxime endothelin antagonist during trialkylsilane/TFA cleavage after solid-phase synthesis. International Journal of Peptide Research and Therapeutics, 1996, 3, 117-120.	0.1	2
229	Synthesis and structure–activity relationship studies of new endothelin pseudopeptide analogues containing alkyl spacers. Il Farmaco, 1999, 54, 213-217.	0.9	2
230	Just a spoonful of sugar: Short glycans affect protein properties and functions. Journal of Peptide Science, 2019, 25, e3167.	1.4	2
231	A SARS–CoV-2 Spike Receptor Binding Motif Peptide Induces Anti-Spike Antibodies in Mice andIs Recognized by COVID-19 Patients. Frontiers in Immunology, 2022, 13, .	4.8	2
232	Tachykinins protect against ethanol induced gastric ulcers in rats. Regulatory Peptides, 1988, 22, 66.	1.9	1
233	Miotic effect of subtance P eye drops in humans. Regulatory Peptides, 1988, 22, 71.	1.9	1
234	Structure-Function analysis of human granulocyte-macrophage colony stimulating factor using synthetic peptides and antibodies. Pharmacological Research, 1992, 26, 192-193.	7.1	1

#	Article	IF	CITATIONS
235	Importance of the C-terminal amide for the biological activity of neurokinin a derivatives. Neuropeptides, 1992, 22, 54.	2.2	1
236	A structure-activity study on the bradykinin B1 antagonist desArg10-HOE 140: The alanine scan. International Journal of Peptide Research and Therapeutics, 1999, 6, 123-127.	0.1	1
237	Assessment of new 6-Cl-HOBt based coupling reagents for peptide synthesis. Part 2: Racemization studies. International Journal of Peptide Research and Therapeutics, 2002, 9, 125-129.	0.1	1
238	Development of an Efficient Multiple Sclerosis Diagnostic Technology Based on an Optical Glycopeptide Immunosensor. , 2006, , 785-786.		1
239	pHâ€regulated formation of side products in the reductive amination approach for differential labeling of peptides in relative quantitative experiments. Electrophoresis, 2014, 35, 1259-1267.	2.4	1
240	Histone Protein Epitope Mapping for Autoantibody Recognition in Rheumatoid Arthritis. Methods in Molecular Biology, 2019, 1901, 221-228.	0.9	1
241	ELISA based on peptide antigens reproducing cross-reactive viral epitopes to detect antibodies in latent autoimmune diabetes in adults vs. type 1 diabetes. MethodsX, 2021, 8, 101452.	1.6	1
242	Tachykinin Receptors in the Longitudinal and Circular Muscle of the Human Ileum. Advances in Experimental Medicine and Biology, 1991, 298, 249-252.	1.6	1
243	SPPS of difficult sequences: A comparison of chemical conditions, synthetic strategies and on-line monitoring. , 1995, , 254-255.		1
244	An Optimized Safe Process from Bench to Pilot cGMP Production of API Eptifibatide Using a Multigram-Scale Microwave-Assisted Solid-Phase Peptide Synthesizer. Organic Process Research and Development, 2021, 25, 2754-2771.	2.7	1
245	Solid-phase synthesis of neurokinin A antagonists. Comparison of the Boc and Fmoc methods. International Journal of Peptide and Protein Research, 1991, 37, 140-4.	0.1	1
246	Tachykinin receptors in the rat lower urinary tract. Regulatory Peptides, 1988, 22, 141.	1.9	0
247	Evidence for heterogeneity off NK-2 tachykinin receptors by using competitive antagonists. European Journal of Pharmacology, 1990, 183, 2141-2142.	3.5	Ο
248	Structure-activity study of R 396, an NK-2 receptor antagonist selective for the NK-2B receptor subtype. Neuropeptides, 1992, 22, 58-59.	2.2	0
249	A new endothelin c-terminal analogue IBDP 064 antagonizes endothelin-3-induced rat glioma cell proliferation. Biomedicine and Pharmacotherapy, 1993, 47, 249.	5.6	0
250	Anchor residue motifs of HLA class I-binding peptides analysed by the direct binding of synthetic peptides to HLA class I alpha chains. Human Immunology, 1993, 36, 67.	2.4	0
251	CD and fluorescence studies of the human granulocyte-macrophage colony-stimulating factor and related peptide conformations in aqueous solution. Biopolymers, 1995, 36, 1-8.	2.4	0
252	Design, synthesis, and conformational studies of the hGM-CSF derived peptide (13-27)-Gly-(75-87). Biopolymers, 1999, 50, 545-554.	2.4	0

PAOLO ROVERO

#	Article	IF	CITATIONS
253	Urotensin-II Receptor Peptide Agonists. ChemInform, 2004, 35, no.	0.0	0
254	New Urotensin-II Analogs Modified at Position 4. , 2006, , 437-438.		0
255	Cross-Reactivity Studies of rMOGED with Synthetic Putative Autoantigens CSF114(Glc) and [N31(Glc)]hMOG(30–50) in Multiple Sclerosis Patients' Sera. , 2006, , 769-770.		0
256	Does an Aberrant Glucosylation Trigger Autoimmunity in Multiple Sclerosis?. , 2006, , 775-776.		0
257	Optimization of Multiple Sclerosis Antigenic Probes by a Combinatorial Approach. , 2006, , 779-780.		0
258	THU0093â€Deiminated Histone 4 from Neutrophil Extracellular Traps is a Novel Autontigen in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A194.2-A194.	0.9	0
259	Lipoylated Peptides and Proteins. Topics in Heterocyclic Chemistry, 2015, , 1.	0.2	0
260	Lipoylated Peptides and Proteins. Topics in Heterocyclic Chemistry, 2015, , 235-252.	0.2	0
261	AB0500â€A Novel DNA-Peptide Complex Detects Anti-DSDNA Antibodies in SLE Sera. Annals of the Rheumatic Diseases, 2016, 75, 1076.3-1076.	0.9	0
262	Emerging Peptide Science in Italy. Peptide Science, 2018, 110, e24096.	1.8	0
263	Conformational Studies of a Glycopeptide Recognized with High Affinity by Autoantibodies in Multiple Sclerosis. , 2001, , 340-341.		0
264	Synthetic Peptides in the Diagnosis of Neurological Diseases. Current Protein and Peptide Science, 2003, 4, 277-284.	1.4	0
265	A Glycopeptide-based Technique for Selective Antibody Purification. Advances in Experimental Medicine and Biology, 2009, 611, 369-370.	1.6	0
266	Ribose Building Block For The Synthesis Of Glycopeptides For Fishing Out Antibodies In Autoimmune Diseases. Advances in Experimental Medicine and Biology, 2009, 611, 441-442.	1.6	0
267	Studies for Identification of the Minimal Epitope(s) mimicked by the Synthetic Glucopeptide CSF114(Glc). Advances in Experimental Medicine and Biology, 2009, 611, 431-432.	1.6	0
268	Semi-Synthetic Strategies to Obtain Glucosylated MOG to Identify Antibodies as Biomarkers in Multiple Sclerosis Disease. Advances in Experimental Medicine and Biology, 2009, 611, 327-328.	1.6	0
269	Comparison of Boc and Fmoc methods in the solid-phase synthesis of hydrophobic peptides. , 1991, , 179-180.		0
270	Conformation-activity relationship on MEN 10376 neurokinin A antagonist: Effect of cyclization. , 1993, , 591-592.		0

#	Article	IF	CITATIONS
271	Structure-activity relationship of neurokinin A analogues as agonists at the NK2 receptor subtypes. , 1993, , 673-674.		0
272	Further evaluation of the secondary anchor residues of HLA-B27-binding peptides. , 1995, , 813-814.		0
273	New Urotensin-II Analogs with a Constrained Trp-7 Side Chain. , 2006, , 439-440.		0
274	Study of Aberrant Modifications in Peptides as a Test Bench to Investigate the Immunological Response to Non-Enzymatic Glycation. Folia Biologica, 2019, 65, 195-202.	0.6	0
275	Role of Helical Structure in MBP Immunodominant Peptides for Efficient IgM Antibody Recognition in Multiple Sclerosis. Frontiers in Chemistry, 0, 10, .	3.6	0